In this activity, Dr. Baljevic discusses patients with newly diagnosed multiple myeloma who are eligible for transplant and reviews recent data from trials evaluating novel multi-drug combinations in the frontline setting. He also identifies the management of treatment-emergent adverse events that are associated with different treatment approaches.

Smoldering multiple myeloma is an asymptomatic stage that occurs in between MGUS and active multiple myeloma. In this activity, Dr. Noopur Raje provides best practice regarding the diagnosis and management choice for patients with smoldering multiple myeloma. Furthermore, she describes the revised 20/2/20 risk stratification model and the implications on treatment decision making.

The treatment of transplant-ineligible patients with newly diagnosed myeloma remains a clinical challenge, but recent developments in novel therapeutic approaches have been shown to improve outcomes in these patients. In this activity, Dr. Usmani reviews the key clinical data in transplant-ineligible, newly diagnosed myeloma, and provides evidence-based recommendations for choosing individualized treatment regimens.

Treating patients with relapsed/refractory multiple myeloma (RRMM) has become more challenging with the introduction of new agents. In this activity, Dr. Lonial discusses the management of RRMM, given the new number of agents available, and which options are the best choice at the different stages of care. He will also review disease-related factors, treatment-related factors, and patient-related factors when considering treatment selection.

Managing a newly diagnosed patient with multiple myeloma can present challenges. In this activity, Dr. Ailawadhi covers the key aspects of treatment for patients living with relapsed or refractory multiple myeloma.